Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma

Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer diagnosed worldwide. CSCC is generally localized and managed with local therapies such as excision and/or radiotherapy. For patients with unresectable or metastatic disease, recent improvements in our understanding of the...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alesha A. Thai, Annette M. Lim, Benjamin J. Solomon, Danny Rischin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	cutaneous squamous cell carcinoma CSCC treatment advances biology immunocompromised Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d012c34f6fe8455b9f888836410ccca0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d012c34f6fe8455b9f888836410ccca0
record_format	dspace
spelling	oai:doaj.org-article:d012c34f6fe8455b9f888836410ccca02021-11-25T17:01:59ZBiology and Treatment Advances in Cutaneous Squamous Cell Carcinoma10.3390/cancers132256452072-6694https://doaj.org/article/d012c34f6fe8455b9f888836410ccca02021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/22/5645https://doaj.org/toc/2072-6694Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer diagnosed worldwide. CSCC is generally localized and managed with local therapies such as excision and/or radiotherapy. For patients with unresectable or metastatic disease, recent improvements in our understanding of the underlying biology have led to significant advancements in treatment approaches—including the use of immune checkpoint inhibition (ICI)—which have resulted in substantial gains in response and survival compared to traditional cytotoxic approaches. However, there is a lack of understanding of the biology underpinning CSCC in immunocompromised patients, in whom the risk of developing CSCC is hundreds of times higher compared to immunocompetent patients. Furthermore, current ICI approaches are associated with significant risk of graft rejection in organ transplant recipients who make up a significant proportion of immunocompromised patients. Ongoing scientific and clinical research efforts are needed in order to maintain momentum to increase our understanding and refine our therapeutic approaches for patients with CSCC.Alesha A. ThaiAnnette M. LimBenjamin J. SolomonDanny RischinMDPI AGarticlecutaneous squamous cell carcinomaCSCCtreatmentadvancesbiologyimmunocompromisedNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5645, p 5645 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cutaneous squamous cell carcinoma CSCC treatment advances biology immunocompromised Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	cutaneous squamous cell carcinoma CSCC treatment advances biology immunocompromised Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Alesha A. Thai Annette M. Lim Benjamin J. Solomon Danny Rischin Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
description	Cutaneous squamous cell carcinoma (CSCC) is the second most common skin cancer diagnosed worldwide. CSCC is generally localized and managed with local therapies such as excision and/or radiotherapy. For patients with unresectable or metastatic disease, recent improvements in our understanding of the underlying biology have led to significant advancements in treatment approaches—including the use of immune checkpoint inhibition (ICI)—which have resulted in substantial gains in response and survival compared to traditional cytotoxic approaches. However, there is a lack of understanding of the biology underpinning CSCC in immunocompromised patients, in whom the risk of developing CSCC is hundreds of times higher compared to immunocompetent patients. Furthermore, current ICI approaches are associated with significant risk of graft rejection in organ transplant recipients who make up a significant proportion of immunocompromised patients. Ongoing scientific and clinical research efforts are needed in order to maintain momentum to increase our understanding and refine our therapeutic approaches for patients with CSCC.
format	article
author	Alesha A. Thai Annette M. Lim Benjamin J. Solomon Danny Rischin
author_facet	Alesha A. Thai Annette M. Lim Benjamin J. Solomon Danny Rischin
author_sort	Alesha A. Thai
title	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
title_short	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
title_full	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
title_fullStr	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
title_full_unstemmed	Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma
title_sort	biology and treatment advances in cutaneous squamous cell carcinoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/d012c34f6fe8455b9f888836410ccca0
work_keys_str_mv	AT aleshaathai biologyandtreatmentadvancesincutaneoussquamouscellcarcinoma AT annettemlim biologyandtreatmentadvancesincutaneoussquamouscellcarcinoma AT benjaminjsolomon biologyandtreatmentadvancesincutaneoussquamouscellcarcinoma AT dannyrischin biologyandtreatmentadvancesincutaneoussquamouscellcarcinoma
_version_	1718412805044961280

Biology and Treatment Advances in Cutaneous Squamous Cell Carcinoma

Ejemplares similares